U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06957886) titled 'A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer' on April 27.
Brief Summary: This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
HER2-low Breast Cancer
Intervention:
DRUG: BL-M07D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel
O...